Patents Assigned to Intradigm Corporation
  • Publication number: 20120115923
    Abstract: This invention describes compositions and methods using siRNA to target various genes expressed in cells of injured tissue during scar formation to promote scar-free wound healing.
    Type: Application
    Filed: December 29, 2006
    Publication date: May 10, 2012
    Applicant: Intradigm Corporation
    Inventors: Wei-Wu He, Patrick Y. Lu
  • Publication number: 20110282093
    Abstract: The invention relates to heterobifunctional polyethylene glycol reagents, methods of producing them and methods of using them.
    Type: Application
    Filed: November 12, 2008
    Publication date: November 17, 2011
    Applicant: Intradigm Corporation
    Inventors: Daniel E. Levy, Samuel Zalipsky, Steven M. Chamow
  • Publication number: 20110046067
    Abstract: The present invention provides nucleic acid molecules that inhibit EGFR expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: June 20, 2008
    Publication date: February 24, 2011
    Applicant: Intradigm Corporation
    Inventors: Xiaodong Yang, Frank Y. Xie, Yijia Liu, Ying Liu
  • Patent number: 7893244
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: February 22, 2011
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Patent number: 7893243
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: February 22, 2011
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Publication number: 20110038849
    Abstract: Compositions and methods for treating diseases, such as cancers. The compositions are effective to silence, down-regulate or suppress the expression of a validated target gene by stimulating the process of RNA interference of gene expression, thus inhibiting tumor growth. The invention also provides methods for treating diseases, such as cancers, by inactivation of a validated target gene product, using neutralizing antibody or small molecule drug, to inhibit tumor growth. More particularly, the compositions and methods are directed toward a cancer or a precancerous growth in a mammal, associated with pathological expression of a certain target genes identified herein. The compositions inhibit expression of the target gene when introduced into a tissue of the mammal. The methods include administering the compositions of the invention to a subject in need thereof in an amount effective to inhibit expression of a target gene in a cancerous tissue or organ.
    Type: Application
    Filed: December 21, 2006
    Publication date: February 17, 2011
    Applicant: Intradigm Corporation
    Inventors: Frank Y. Xie, Patrick Y. Lu, Martin C. Woodle, Yijia Liu
  • Patent number: 7786092
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: August 31, 2010
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Patent number: 7781414
    Abstract: The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: August 24, 2010
    Assignee: Intradigm Corporation
    Inventors: Patrick Y. Lu, Frank Y. Xie, Martin C. Woodle, Yijia Liu, Quinn Q. Tang, Jun Xu
  • Patent number: 7723316
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: May 25, 2010
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Publication number: 20100028848
    Abstract: This invention describes compositions and methods using siRNA to target various genes expressed in cells of transplanted organs or tissues and/or genes expressed in the host to improve the success of the transplantation.
    Type: Application
    Filed: November 30, 2006
    Publication date: February 4, 2010
    Applicant: Intradigm Corporation
    Inventors: Marie Denise Parker, Julian Roy Pratt, Yijia Liu, Yang Lu, Martin Woodle, Yuefeng Xie
  • Publication number: 20090247604
    Abstract: Compositions and methods for treating ocular disease are provided. Specifically, siRNA molecules and mixtures of siRNA molecules are provided that inhibit angiogenesis and/or neovascularization. The compositions and methods are suitable for treating ocular diseases associated with angiogenesis and/or neovascularization.
    Type: Application
    Filed: February 7, 2005
    Publication date: October 1, 2009
    Applicant: Intradigm Corporation
    Inventors: Quinn Tang, Patrick Y. Lu, Frank Y. Xie, Martin C. Woodle
  • Publication number: 20090227657
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Application
    Filed: April 9, 2009
    Publication date: September 10, 2009
    Applicant: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Patent number: 7534878
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: May 19, 2009
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Publication number: 20080279920
    Abstract: The invention provides siRNA compositions that interfere with viral replication in respiratory viral infections, including respiratory syncytial virus and avian influenza A, including the H5N1 strain. The invention further provides uses of the siRNA compositions to inhibit expression of viral genes in respiratory virus-infected cells, and to uses in the treatment of respiratory virus infections in a subject. Generally the invention provides polynucleotide that includes a first nucleotide sequence of 15 to 30 bases that targets the genome of a respiratory syncytial virus or an influenza A virus, a complement thereof, a double stranded polynucleotide or a hairpin polynucleotide. Additionally the invention provides vectors, cells and pharmaceutical compositions containing siRNA sequences.
    Type: Application
    Filed: November 4, 2005
    Publication date: November 13, 2008
    Applicant: Intradigm Corporation
    Inventors: Qingquan Tang, Patrick Y. Lu, Frank Y. Xie, Martin C. Woodle, Bojian Zheng
  • Publication number: 20070203082
    Abstract: The present invention provides compositions and methods that are useful for the treatment of severe acute respiratory syndrome (SARS). More specifically, nucleic acid agents such as siRNA molecules and their analogues that target respiratory infections including SARS coronavirus and their methods of use are described, for clinical treatments of SARS, respiratory viral infections, for prevention and treatment of respiratory infections as needed for bio-defense, for treatment of respiratory diseases, and for discovery of therapeutic targets for respiratory diseases and infections.
    Type: Application
    Filed: April 26, 2004
    Publication date: August 30, 2007
    Applicant: Intradigm Corporation
    Inventors: Quinn Tang, Patrick Lu, Frank Xie, Yija Liu, Jun Xu, Martin Woodle
  • Publication number: 20060211637
    Abstract: Methods and compositions are provided for down regulation of target gene expression in vivo by RNA interference. The methods are useful for target discovery and validation of gene-based drug development, and for treatment of human diseases.
    Type: Application
    Filed: August 6, 2003
    Publication date: September 21, 2006
    Applicant: Intradigm Corporation
    Inventors: Puthupparampil Scaria, Martin Woodle, Patrick Lu, Qingquan Tang, Jun Xu, Frank Xie